Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,046 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

NCT05049733
View directory record Official record
Conditions
Cannabis
Interventions
CBD 1mg/Kg, CBD 2mg/Kg, CBD 4mg/Kg, Placebo CBD
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 18, 2026, 3:23 AM EDT
Active, not recruiting Phase 2 Interventional

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685
View directory record Official record
Conditions
Glioma of Brain
Interventions
Mirtazapine (Remeron)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 1 Interventional

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

NCT01316185
View directory record Official record
Conditions
Hepatitis D
Interventions
EBP921
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
San Francisco, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 18, 2026, 3:23 AM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

NCT00585780
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Prazosin Tablet, Placebo Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Resveratrol, resveratrol /HMB, Placebo treatment
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 18, 2026, 3:23 AM EDT
Not listed Not applicable Interventional

Smoking Cessation for People Living With HIV/AIDS

NCT01965405
View directory record Official record
Conditions
HIV, AIDS, Nicotine Dependence
Interventions
Bupropion, Brief Counseling, High-magnitude prize contingency management, Monitored support to quit smoking, No additional treatment, Prize contingency management for abstinence, Low intensity prize contingency management
Drug · Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Early Phase 1 Interventional

Combined IV and Topical TXA in Major Spine Surgery

NCT04797156
View directory record Official record
Conditions
Spine Surgery, Back Pain
Interventions
High Dose Tranexamic acid, Low Dose Tranexamic acid, Tranexamic acid Topical, Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

NCT02642159
View directory record Official record
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01875003
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Standard of Care
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity

NCT05289869
View directory record Official record
Conditions
Pregnant Patients With Obesity
Interventions
High-dose oxytocin, Low-dose oxytocin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 18, 2026, 3:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

NCT01898494
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

NCT00057356
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
conivaptan, placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Huntsville, Alabama • Los Angeles, California • Manteca, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

NCT00019682
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Aldesleukin, gp100 Antigen, Montanide ISA 51 VG, Quality-of-Life Assessment, Questionnaire Administration, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

NCT04780841
View directory record Official record
Conditions
Hyperkalemia
Interventions
RDX013, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 18, 2026, 3:23 AM EDT
Active, not recruiting Phase 3 Interventional

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

NCT05336786
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Perflutren Lipid Microspheres, Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ultra High Dose Diuretics to Treat Heart Failure

NCT06036914
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
Bumetanide, Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Motivation to Exercise

NCT02444247
View directory record Official record
Conditions
Overweight, Obesity, Physical Activity
Interventions
High Dose Exercise (300 kcal), Low Dose Exercise (150 kcal), No Exercise (0 kcal), Sedentary Option
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 49 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

NCT02370485
View directory record Official record
Conditions
Healthy
Interventions
LY2801653
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

NCT00462735
View directory record Official record
Conditions
Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions
Cetuximab, Hydroxyurea, Fluorouracil, radiotherapy
Drug · Procedure
Lead sponsor
Johnny Kao
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 18, 2026, 3:23 AM EDT